-
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Tuesday, July 23, 2024 - 3:05pm | 483Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:BDX). The medical technology company, which...
-
House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month
Friday, April 1, 2022 - 7:20am | 316The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare. The vote was 232 (yes)-193 (no), with 12 Republican members joining their Democratic colleagues to pass the measure. The Affordable...
-
Novo Nordisk Settles Insulin Pricing Lawsuit For $100M
Monday, September 27, 2021 - 3:57pm | 467Novo Nordisk A/S (NYSE: NVO) has agreed to pay $100 million to settle a 2017 investor suit that alleged the Company failed to disclose that it was under the same pricing pressures as its competitors. Related Content: House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On...
-
House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices
Friday, August 20, 2021 - 2:34pm | 444House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supposed concern over the past two years with the price...
-
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
Monday, August 16, 2021 - 3:01pm | 180The FDA has approved the use of Eli Lilly And Co's (NYSE: LLY) Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's (NASDAQ: PODD) insulin management systems. Lyumjev, approved by the FDA in June 2020, is a formulation of insulin...
-
Viatris Stock Gains After FDA Approves Viatris-Biocon Biologics' Insulin Glargine Biosimilar Injection
Thursday, July 29, 2021 - 8:04am | 230The FDA cleared Viatris inc (NASDAQ: VTRS) - Biocon Biologics' Semglee insulin glargine-yfgn injection as a biosimilar. Semglee indicates controlling high blood sugar in adults with type 2 diabetes and pediatric patients with type 1 diabetes. The FDA approved Semglee...
-
Eli Lilly To Look For Ways To Cut Insulin Costs After Walmart Debut: CNBC
Tuesday, June 29, 2021 - 3:11pm | 306Eli Lilly And Co (NYSE: LLY) CEO David Ricks said he welcomes new competition from Walmart Inc (NYSE: WMT) even as the retailer undercuts the company's insulin prices. Walmart announced Tuesday is launching its first-ever private label insulin analog, available exclusively...
-
Walmart, Novo Nordisk Unveil Own Low-Cost Brand Insulin
Tuesday, June 29, 2021 - 8:51am | 191Walmart Inc (NYSE: WMT) is launching its first-ever private label insulin analog, available exclusively at its stores. The company worked directly with manufacturer Novo Nordisk A/S (NYSE: NVO) on ReliOn Novolog, allowing it to offer the product in both vials and FlexPens at a...
-
Sanofi's Soliqua Shows Improved Blood Sugar Control Without Weigh Gain Against Premixed Insulin
Monday, June 28, 2021 - 12:40pm | 205Sanofi SA (NASDAQ: SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin in type 2 diabetes. The data were presented...
-
Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin
Wednesday, December 18, 2019 - 12:07pm | 756Eli Lilly And Co (NYSE: LLY) CEO David Ricks said Tuesday that U.S. Sen. Elizabeth Warren’s criticism of the cost of the drugmaker's insulin is “nonsense.” Warren Says Eli Lilly Broke Promise On Insulin In a Monday Facebook post, the Democratic presidential candidate denounced...
-
Tandem Diabetes Says Death Of Patient Wasn't Due To Insulin Pump Malfunction
Friday, November 8, 2019 - 3:15pm | 255Tandem Diabetes Care Inc (NASDAQ: TNDM) shares traded lower Friday after a report of the death of a patient using Tandem’s T:SLIM X2 insulin pump was added to the Food and Drug Administration’s Adverse Event report system. The report said the patient’s blood glucose was low at the...
-
Valeritas Stock Should More Than Double, Oppenheimer Says
Thursday, July 5, 2018 - 12:41pm | 396Valeritas Holdings Inc (NASDAQ: VLRX), a medical technology company known for its V-Go Wearable Insulin Delivery device, could more than double in value, according to Oppenheimer. The Analyst Oppenheimer's Steven Lichtman initiated coverage of Valeritas with an Outperform rating and 12- to 18-...
-
4 Tailwinds Driving Raymond James' Insulet Bull Case
Monday, January 8, 2018 - 1:22pm | 482Raymond James identified four major tailwinds for Insulet Corporation (NASDAQ: PODD) that the firm said could help drive 20-percent-plus revenue growth over the next two years. The Analyst Raymond James analyst Jayson Bedford upgraded Insulet from Market Perform from Outperform with an $80...
-
New Label For Afrezza Could Turn Things Around At MannKind
Tuesday, October 10, 2017 - 10:21am | 438Despite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of...
-
New Report Questions Insulet Management's 'Baseless' Claims: 'Investors Being Led To The Slaughter'
Tuesday, November 29, 2016 - 11:16am | 611SkyTides has followed up on a report from November 15 that Insulet Corporation (NASDAQ: PODD) has covered up patient deaths related to its Omnipod insulin pump. The report contained what SkyTides believes were 44 undisclosed Omnipod patient deaths and 51 FDA complaints that the product put...